CHEMOMETEC A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 306.2 DKK | +0.39% |
|
-0.64% | -20.10% |
| 27/05 | Denmark's ChemoMetec Appoints New CFO | MT |
| 24/05 | ChemoMetec A/S Announces CFO Changes | CI |
Valuation
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 14,679 | 13,174 | 8,110 | 5,308 | - | - |
| Enterprise Value (EV) 1 | 14,679 | 13,174 | 7,800 | 4,970 | 4,911 | 4,858 |
| P/E ratio | 166 x | 82.6 x | 45.4 x | 41.6 x | 34.7 x | 29.3 x |
| Yield | - | 0.53% | - | 1.42% | 1.75% | 1.86% |
| Capitalization / Revenue | - | 30.8 x | 18.3 x | 13.1 x | 11.5 x | 10 x |
| EV / Revenue | - | 30.8 x | 17.6 x | 12.3 x | 10.7 x | 9.17 x |
| EV / EBITDA | - | 59.1 x | 31.1 x | 26.5 x | 22.6 x | 19 x |
| EV / FCF | - | - | 68.8 x | 51.5 x | 36.4 x | 32.9 x |
| FCF Yield | - | - | 1.45% | 1.94% | 2.75% | 3.04% |
| Price to Book | - | - | 15.2 x | 8.98 x | 7.94 x | 7.02 x |
| Nbr of stocks (in thousands) | 17,402 | 17,402 | 17,402 | 17,402 | - | - |
| Reference price 2 | 843.5 | 757.0 | 466.0 | 305.0 | 305.0 | 305.0 |
| Announcement Date | 17/09/21 | 15/09/22 | 13/09/23 | - | - | - |
1DKK in Million2DKK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 427.2 | 442.3 | 404.3 | 460.6 | 529.8 |
| EBITDA 1 | - | 222.9 | 251 | 187.2 | 217 | 255.8 |
| EBIT 1 | - | 202.9 | 230.6 | 167.8 | 195.6 | 231.7 |
| Operating Margin | - | 47.48% | 52.13% | 41.52% | 42.47% | 43.73% |
| Earnings before Tax (EBT) 1 | - | - | 230.4 | 168.9 | 195.8 | 231.6 |
| Net income 1 | 88.35 | 159.5 | 178.7 | 127.3 | 152.8 | 181 |
| Net margin | - | 37.34% | 40.4% | 31.5% | 33.17% | 34.16% |
| EPS 2 | 5.080 | 9.160 | 10.27 | 7.326 | 8.780 | 10.40 |
| Free Cash Flow 1 | - | - | 113.3 | 96.5 | 135 | 147.7 |
| FCF margin | - | - | 25.62% | 23.87% | 29.31% | 27.87% |
| FCF Conversion (EBITDA) | - | - | 45.15% | 51.55% | 62.22% | 57.72% |
| FCF Conversion (Net income) | - | - | 63.43% | 75.78% | 88.37% | 81.59% |
| Dividend per Share 2 | - | 4.000 | - | 4.333 | 5.333 | 5.667 |
| Announcement Date | 17/09/21 | 15/09/22 | 13/09/23 | - | - | - |
1DKK in Million2DKK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 108.1 | 199.3 | 98.9 | 105.5 | 203 | 216 | 224 |
| EBITDA 1 | 51.6 | 93.1 | 43.1 | 49.2 | 91 | 101 | 96 |
| EBIT 1 | - | 84.65 | 43.5 | 49.2 | 82 | 92 | 86 |
| Operating Margin | - | 42.47% | 43.98% | 46.64% | 40.39% | 42.59% | 38.39% |
| Earnings before Tax (EBT) | - | 89.02 | - | - | 83 | 93 | 88 |
| Net income 1 | - | 70.56 | 43.5 | 49.2 | 65 | 72 | 68 |
| Net margin | - | 35.4% | 43.98% | 46.64% | 32.02% | 33.33% | 30.36% |
| EPS 2 | - | 4.050 | 2.500 | 2.830 | 3.720 | 4.160 | 3.920 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 05/02/24 | 05/02/24 | 08/05/24 | - | - | - | - |
1DKK in Million2DKK
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 309 | 338 | 396 | 450 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 113 | 96.5 | 135 | 148 |
| ROE (net income / shareholders' equity) | - | 51.4% | 39.5% | 22.7% | 24.5% | 26.2% |
| ROA (Net income/ Total Assets) | - | - | - | 19.4% | 19.6% | 21.1% |
| Assets 1 | - | - | - | 657.7 | 778.9 | 859.4 |
| Book Value Per Share 2 | - | - | 30.60 | 34.00 | 38.40 | 43.50 |
| Cash Flow per Share 2 | - | 10.20 | 8.860 | 8.000 | 10.40 | 12.20 |
| Capex 1 | - | - | 40.8 | 52.5 | 42.1 | 51.7 |
| Capex / Sales | - | - | 9.23% | 12.99% | 9.14% | 9.76% |
| Announcement Date | 17/09/21 | 15/09/22 | 13/09/23 | - | - | - |
1DKK in Million2DKK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
305
DKK
Average target price
437.5
DKK
Spread / Average Target
+43.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.10% | 762M | |
| +12.99% | 7.03B | |
| -31.51% | 6.68B | |
| +8.94% | 5.25B | |
| -19.33% | 4.67B | |
| +14.44% | 4.07B | |
| -20.81% | 3.77B | |
| -29.50% | 2.66B | |
| +20.83% | 1.94B | |
| -1.61% | 1.99B |
- Stock Market
- Equities
- CHEMM Stock
- Financials ChemoMetec A/S
